BNTC - Benitec Biopharma Limited

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.65
-0.05 (-1.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.70
Open2.65
Bid0.10 x 800
Ask3.80 x 1800
Day's Range2.65 - 2.70
52 Week Range1.85 - 4.90
Volume8,971
Avg. Volume89,985
Market Cap35.992M
Beta4.20
PE Ratio (TTM)N/A
EPS (TTM)-0.80
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Foollast month

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks get even hotter?

  • Axovant, Benitec Gain on Licensing Deal for Gene Therapy
    Zackslast month

    Axovant, Benitec Gain on Licensing Deal for Gene Therapy

    Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Benitec Biopharma and Pfizer

    NEW YORK, NY / ACCESSWIRE / July 10, 2018 / Shares of Pfizer may have ended up flat yesterday but it wasn't the greatest news day for the pharmaceutical giant. President Trump took to Twitter to raise his concerns on the company as well as other drug makers for recently increasing prices. Shares of Benitec Biopharma was a big winner and even hit a new high after announcing a licensing agreement with Axovant.

  • ACCESSWIRElast month

    New Catalysts Could Send This $3 Medical Device Stock to $9

    New entrant Biotricity (BTCY) is jumping into the same market with a potentially superior product and under-appreciated market valuation. BTCY expects to be prepared with two more products in the next 6-9 months, and they could all be on the market by the end of 2019. NEW YORK, NY / ACCESSWIRE / July 10, 2018 / With their latest investor update, Biotricity Inc. (BTCY) just dropped a major hint that most investors have been missing so far... key product updates are coming later this year.

  • Axovant and Benitec Biopharma Up on Gene Therapy Development Deal
    Market Realistlast month

    Axovant and Benitec Biopharma Up on Gene Therapy Development Deal

    Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal

  • TheStreet.comlast month

    Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD

    Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.

  • PR Newswirelast month

    Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant

    - Benitec to receive upfront cash payment of US$10 million with additional cash payments totalling US$17.5 million (a total of US$27.5M ) upon completion of near-term milestones for BB-301, now named AXO-AAV-OPMD ...

  • PR Newswire3 months ago

    Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update

    NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy with its patented gene-silencing technology called ddRNAi or 'expressed RNAi', today reported its consolidated financial results for the 2018 fiscal third quarter to 31 March 2018 (3Q FY18), and highlighted recent progress advancing its pipeline.

  • PR Newswire3 months ago

    Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting

    SYDNEY , May 15, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) today announced that data from its oculopharyngeal muscular dystrophy (OPMD) program will be presented ...

  • PR Newswire4 months ago

    Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program

    - Details on the Company's OPMD program and roadmap to be presented by Benitec Management Team - Discussion on disease and market to be presented by internationally renowned key opinion leader Bernard ...

  • ASX/NASDAQ Announcement
    PR Newswire4 months ago

    ASX/NASDAQ Announcement

    NASDAQ: BNTCW) today provided an update on its two lead programs in head and neck squamous cell carcinoma (HNSCC) and oculopharyngeal muscular dystrophy (OPMD).  This update should be read in conjunction with the latest corporate presentation which can be found on the Company's website. The first clinical site has now been opened in Australia and the Company anticipates having additional Australian sites open later this month.  Regulatory review with the Ministry of Health is ongoing in Russia and the Company expects approval at the end of May.

  • PR Newswire6 months ago

    Benitec Biopharma Launches its Phase 2 Oncology Study in Australia

    NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative therapeutics based on a combination of gene therapy and its patented gene-silencing technology named ddRNAi or 'expressed RNAi', today announced the start of its Phase 2 clinical study in Australia with BB-401 as a treatment for patients with head and neck squamous cell carcinoma (HNSCC). The Phase 2 open label study has been designed to explore the safety, tolerability and efficacy of BB-401 following intratumoral injections into the lesions of patients with recurrent or metastatic HNSCC.  The study will enrol up to 30 patients at 5-8 sites across Australia and Russia.  The trial is registered on www.clinicaltrials.gov with the identifier: NCT03433027, where more details can be found.

  • PR Newswire6 months ago

    Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update

    SYDNEY , Feb. 22, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) ("Benitec" or "the Company"), a biotechnology company developing innovative ...

  • PR Newswire7 months ago

    Federal R&D Tax Credit Received

    SYDNEY , Jan. 23, 2018 /PRNewswire/ -- Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) advises that it has received a $4,112,058 cash refund for the year ended 2017 under the Federal ...

  • PR Newswire7 months ago

    Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy

    NASDAQ: BNTCW) today announced that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to BB-301 for the treatment of oculopharyngeal muscular dystrophy (OPMD). The Orphan Drug Designation granted to Benitec may provide a range of valuable benefits, including fast track process for clinical regulatory approval, potential extension of patent life with a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees.  In short, a clear and expeditious path for cost-efficient development and commercialisation.

  • TheStreet.com9 months ago

    Alkermes Jumps on License Deal With Biogen -- Biotech Movers

    Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.

  • PR Newswire9 months ago

    Benitec Biopharma provides update on OPMD orphan disease program

    NASDAQ:BNTCW) is pleased to announce it has submitted an application with the U.S. Food & Drug Administration (FDA) seeking orphan drug designation for BB-301 as a treatment of oculopharyngeal muscular dystrophy (OPMD). BB-301 is a single vector (gene therapy construct) system which uses DNA directed RNA interference (ddRNAi) to silence expression of the mutant gene associated with OPMD, while simultaneously adding back a copy of the normal version of the same gene to restore gene function. To receive orphan drug designation from the FDA, a company must demonstrate that the condition addressed by the drug or biologic affects less than 200,000 persons in the U.S.  The company must also provide the FDA with sufficient information to establish a medically plausible basis for expecting the product will be an effective treatment.

  • PR Newswire10 months ago

    U.S. patent granted for Benitec hepatitis B program

    SYDNEY , Oct. 18, 2017 /PRNewswire/ -- Benitec Biopharma Limited (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is pleased to announce that a new patent relating to the Company's hepatitis B program has been issued ...

  • Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017
    Capital Cube11 months ago

    Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017

    Categories: Yahoo FinanceGet free summary analysis Benitec Biopharma Ltd. reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Benitec Biopharma Ltd. – Ionis Pharmaceuticals, Inc. and Affimed N.V. (IONS-US and AFMD-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 0.12 million, ... Read more (Read more...)